Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591447 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea
A Phase 2 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01591447 is a Phase 2 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT01591447, a Phase 2 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.
Interventions
- DRUG solithromycin
- DRUG Solithromycin (CEM-101)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591447
The ClinicalTrials.gov registry entry for NCT01591447 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which solithromycin is the first listed.
NCT01591447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591447 about?
NCT01591447 is a clinical study titled "Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea". To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.
What is the current status of trial NCT01591447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01591447?
The interventions under investigation include: solithromycin (DRUG), Solithromycin (CEM-101) (DRUG).
Who is sponsoring clinical trial NCT01591447?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.